Plant Comparison
Hawthorn vs Lingzhi
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Hawthorn and Lingzhi: they share 6 indicated uses (arthritis / joint pain, cancer (anticancer research), cardiovascular / heart health, …); 4 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Hawthorn | Lingzhi | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cancer (anticancer research) | 2/10 | 8/10 | Stronger for Lingzhi |
| Cardiovascular / heart health | 1/10 | 1/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Insomnia / sleeplessness | 1/10 | 1/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Principal cardioprotective and antioxidant polyphenols characterised by chemical profiling of leaf, flower and fruit.
Contribute to the vasoactive and antioxidant effects, the basis for extract standardisation.
Principal immunomodulatory constituents, the main focus of anticancer-adjunct and immune research.
Bitter triterpenes associated with anti-inflammatory, hepatoprotective and adaptogenic activity.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
inferred from antidiabetic action
inferred from anticancer action
inferred from antiviral action
inferred from anti-inflammatory action
inferred from sedative action
inferred from antidiabetic action
Safety, Cautions & Contraindications
Generally well tolerated. Hawthorn should not replace prescribed cardiac medications without medical supervision. May potentiate the effects of cardiac glycosides (digoxin), antihypertensive drugs, and coronary dilators. Not recommended during pregnancy and breastfeeding due to insufficient safety data. Mild side effects (nausea, dizziness, GI upset) occasionally reported.
Duke (2002) rates hawthorn as +++ — one of the most clinically supported cardiovascular herbs. Clinical evidence (score 2) supports its use for decreasing cardiac output (NYHA functional Stage II heart failure), as recognized by Commission E. Key activities include vasodilation, positive inotropic effects, and antioxidant protection of vascular tissue. Dose: 160–900 mg standardized leaf/flower extract (containing 18.75% oligomeric proanthocyanidins) daily. Duke emphasizes that hawthorn should not replace conventional heart failure therapy, and therapeutic effects may take 4–8 weeks to emerge. Mild interactions with cardiac glycosides (digitalis) are possible (Duke, 2002).
Generally well tolerated at standard doses. May cause mild digestive upset, dry mouth, or dizziness in some individuals. May enhance the effects of anticoagulant and antihypertensive medications. Avoid during pregnancy and breastfeeding. Extended use beyond 6 months is not well studied in humans.
Duke (2002) rates reishi (Ganoderma lucidum) as + and notes immunostimulant, hepatoprotective, antioxidant, antitumor, and hypoglycemic activities at the experimental level (score 1). It is a key adaptogen in traditional Chinese medicine, valued for its polysaccharide (beta-glucan) content. Duke notes antiviral (score 1) and anti-aggregant activities. No strong clinical trials existed at time of publication, but lentinan and polysaccharide fractions from related species show immunomodulatory potential. Duke suggests caution in bleeding disorders due to anti-aggregant activity (Duke, 2002).
External Ids
Botanical Description
Small deciduous tree or large shrub, densely thorny, with deeply lobed, glossy leaves (more deeply cut than midland hawthorn). Clusters of small, five-petalled white flowers with a strong, musky scent appear in spring ('May blossom'), followed by small red berries (haws), each containing a single seed (nutlet) - the origin of the species name monogyna.[4]
Bracket (shelf) fungus (not a true plant) that grows on the trunks and stumps of deciduous trees. It develops a hard, kidney- or fan-shaped cap with a glossy, varnished, red-brown to mahogany crust and concentric growth rings, often on a lateral woody stalk; the pale underside is covered in fine pores that release rusty-brown spores. The mycelium spreads through the wood substrate before fruiting.[1]
Habitat
One of the commonest hedgerow and scrub trees of Europe, growing in hedgerows, woodland edges, scrub and pasture on a wide range of soils; native to Europe, North Africa and Western Asia.[4]
Grows as a wood-decay fungus on the stumps and trunks of deciduous trees (notably maple and other hardwoods) in East Asian forests; also widely cultivated commercially on hardwood logs or sawdust substrate.
Harvesting
Flowers are picked as they open in May, leaves are picked with the young flowering shoots, and the ripe red berries (haws) are gathered in autumn after the first frosts soften them slightly; all three parts are traditionally combined.[4]
Wild fruiting bodies are collected once mature; cultivated material is harvested from logs or substrate at maturity, then dried and processed into slices, powder or extract.
Traditional Uses
Common hawthorn shares the same long cardiovascular and calming tradition as midland hawthorn, used across European herbal medicine as a heart tonic for mild circulatory complaints, palpitations and nervous tension, and remains one of the most clinically studied cardiovascular botanicals.[4]
Reishi/lingzhi, the 'mushroom of immortality', is one of the most revered tonic fungi in traditional Chinese medicine, used for centuries to support vitality, calm the spirit, strengthen immunity and promote longevity; this traditional tonic reputation is now studied for immunomodulatory, anticancer-adjunct and metabolic effects.[1, 4]
Preparations
Leaf-and-flower extract standardised to flavonoid or procyanidin content, taken as tablets or capsules; the best-studied clinical form.
Dosage
The EU herbal monograph on Crataegus spp., folium cum flore gives dry extracts in divided daily doses of 240-900 mg (single dose 80-450 mg) or, for one quantified extract, 570-1750 mg daily (single dose 190-350 mg), in adults and elderly. If symptoms persist longer than 2 weeks a doctor should be consulted, and hawthorn is never used as a substitute for prescribed heart medication without medical supervision. Educational reference only, not a prescription.
The EU herbal monograph gives 1-2 g of the comminuted leaf and flower in 150 mL of boiling water as an infusion, up to 4 times daily (maximum 6 g daily), in adults and elderly. Educational reference only, not a prescription.
Not documented
References
Drug Class Interactions
Lookalikes Review
Dangerous Lookalikes
Not documented
References & Sources
- Ez-Zahra Amrati, F., Mssillou, I., Boukhira, S., Djiddi Bichara, M. et al (2024) 'Phenolic Composition of Crataegus monogyna Jacq. Extract and Its Anti-Inflammatory, Hepatoprotective, and Antileukemia Effects', Pharmaceuticals (Basel), 17(6), pp. 786. doi:10.3390/ph17060786 Preclinical
https://doi.org/10.3390/ph17060786 - Lis, M., Szczypka, M., Suszko-Pawłowska, A., Sokół-Łętowska, A. et al (2019) 'Hawthorn (Crataegus monogyna) Phenolic Extract Modulates Lymphocyte Subsets and Humoral Immune Response in Mice', Planta Medica, 86(2), pp. 160-168. doi:10.1055/a-1045-5437 Preclinical
https://doi.org/10.1055/a-1045-5437 - Paun, G., Neagu, E., Albu, C., Alecu, A. et al (2024) 'Antioxidant and Antidiabetic Activity of Crataegus monogyna L. and Cornus mas Fruit Extracts', Molecules, 29(15), pp. 3595. doi:10.3390/molecules29153595 Preclinical
https://doi.org/10.3390/molecules29153595 - Nabavi, S.F., Habtemariam, S., Ahmed, T., Sureda, A., Daglia, M. and Sobarzo-Sanchez, E (2015) 'Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications', Nutrients, 7(9), pp. 7708-7728. doi:10.3390/nu7095361 Meta-analysis / review
https://doi.org/10.3390/nu7095361 - Belabdelli, F., Bekhti, N., Piras, A., Benhafsa, F.M., Ilham, M. and Adil, S (2021) 'Chemical composition, antioxidant and antibacterial activity of Crataegus monogyna leaves' extracts', Natural Product Research, 36(12), pp. 3234-3239. doi:10.1080/14786419.2021.1958215 Preclinical
https://doi.org/10.1080/14786419.2021.1958215 - Jalali, A.S., Hasanzadeh, S. and Malekinejad, H (2012) 'Crataegus monogyna aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences', Acta Medica Iranica, 50(1), pp. 1-8. Preclinical
https://scholar.google.com/scholar?q=Crataegus%20monogyna%20aqueous%20extract%20ameliorates%20cyclophosphamide-induced%20toxicity%20in%20rat%20testis%3A%20stereological%20evidences - Martin-Garcia, B., Razola-Diaz, M.D.C., Gomez-Caravaca, A.M., Benitez, G. and Verardo, V (2021) 'Setup of an Ultrasonic-Assisted Extraction to Obtain High Phenolic Recovery in Crataegus monogyna Leaves', Molecules, 26(15), pp. 4536. doi:10.3390/molecules26154536 Preclinical
https://doi.org/10.3390/molecules26154536 - Arslan, R., Bektas, N., Bor, Z. and Sener, E (2014) 'Evaluation of the antithrombotic effects of Crataegus monogyna and Crataegus davisii in the carrageenan-induced tail thrombosis model', Pharmaceutical Biology, 53(2), pp. 275-279. doi:10.3109/13880209.2014.914957 Preclinical
https://doi.org/10.3109/13880209.2014.914957 - Edwards, J.E., Brown, P.N., Talent, N., Dickinson, T.A. and Shipley, P.R (2012) 'A review of the chemistry of the genus Crataegus', Phytochemistry, 79, pp. 5-26. doi:10.1016/j.phytochem.2012.04.006 Meta-analysis / review
https://doi.org/10.1016/j.phytochem.2012.04.006 - Jarzycka, A., Lewinska, A., Gancarz, R. and Wilk, K.A (2013) 'Assessment of extracts of Helichrysum arenarium, Crataegus monogyna, Sambucus nigra in photoprotective UVA and UVB; photostability in cosmetic emulsions', Journal of Photochemistry and Photobiology B: Biology, 128, pp. 50-57. doi:10.1016/j.jphotobiol.2013.07.029 Preclinical
https://doi.org/10.1016/j.jphotobiol.2013.07.029 - Lucconi, G., Chlapanidas, T., Martino, E., Gaggeri, R., Perteghella, S. and Rossi, D (2013) 'Formulation of microspheres containing Crataegus monogyna Jacq. extract with free radical scavenging activity', Pharmaceutical Development and Technology, 19(1), pp. 65-72. doi:10.3109/10837450.2012.752387 Preclinical
https://doi.org/10.3109/10837450.2012.752387 - Zorniak, M., Szydlo, B. and Krzeminski, T.F (2017) 'Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences', Journal of Physiology and Pharmacology, 68(4), pp. 521-526. Meta-analysis / review
https://scholar.google.com/scholar?q=Crataegus%20special%20extract%20WS%201442%3A%20up-to-date%20review%20of%20experimental%20and%20clinical%20experiences - European Medicines Agency (2016) 'European Union herbal monograph on Crataegus spp., folium cum flore'. Traditional / reference
https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Crataegus%20spp.%2C%20folium%20cum%20flore - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure'. Traditional / reference
https://scholar.google.com/scholar?q=Hawthorn%20extract%20for%20treating%20chronic%20heart%20failure - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Tankanow, R., Tamer, H.R., Streetman, D.S., Smith, S.G., Welton, J.L., Annesley, T., Aaronson, K.D. and Bleske, B.E (2003) 'Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha)', Journal of Clinical Pharmacology, 43(6), pp. 637-642. doi:10.1177/0091270003253417 Randomized trial
https://doi.org/10.1177/0091270003253417 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003
- Li, W., Zhou, Q., Lv, B., Li, N. et al (2024) 'Ganoderma lucidum Polysaccharide Supplementation Significantly Activates T-Cell-Mediated Antitumor Immunity and Enhances Anti-PD-1 Immunotherapy Efficacy in Colorectal Cancer', Journal of Agricultural and Food Chemistry, 72(21), pp. 12072-12082. doi:10.1021/acs.jafc.3c08385 Preclinical
https://doi.org/10.1021/acs.jafc.3c08385 - Cai, Q., Li, Y. and Pei, G (2017) 'Polysaccharides from Ganoderma lucidum attenuate microglia-mediated neuroinflammation and modulate microglial phagocytosis and behavioural response', Journal of Neuroinflammation, 14(1), pp. 63. doi:10.1186/s12974-017-0839-0 Preclinical
https://doi.org/10.1186/s12974-017-0839-0 - Zheng, G., Zhao, Y., Li, Z., Hua, Y. et al (2023) 'Ganoderma lucidum spore powder and derived triterpenes attenuate atherosclerosis and aortic calcification by stimulating ABCA1/G1-mediated macrophage cholesterol efflux and inactivating RUNX2-mediated VSMC osteogenesis', Theranostics, 13(4), pp. 1325-1341. doi:10.7150/thno.80250 Preclinical
https://doi.org/10.7150/thno.80250 - Sohretoglu, D. and Huang, S (2018) 'Ganoderma lucidum Polysaccharides as An Anti-cancer Agent', Anti-Cancer Agents in Medicinal Chemistry, 18(5), pp. 667-674. doi:10.2174/1871520617666171113121246 Meta-analysis / review
https://doi.org/10.2174/1871520617666171113121246 - Seweryn, E., Ziala, A. and Gamian, A (2021) 'Health-Promoting of Polysaccharides Extracted from Ganoderma lucidum', Nutrients, 13(8), pp. 2725. doi:10.3390/nu13082725 Meta-analysis / review
https://doi.org/10.3390/nu13082725 - Liu, X., Yang, L., Li, G., Jiang, Y., Zhang, G. and Ling, J (2022) 'A novel promising neuroprotective agent: Ganoderma lucidum polysaccharide', International Journal of Biological Macromolecules, 229, pp. 168-180. doi:10.1016/j.ijbiomac.2022.12.276 Meta-analysis / review
https://doi.org/10.1016/j.ijbiomac.2022.12.276 - Zhu, M., Chang, Q., Wong, L.K., Chong, F.S. and Li, R.C (1999) 'Triterpene antioxidants from Ganoderma lucidum', Phytotherapy Research, 13(6), pp. 529-531. doi:10.1002/(sici)1099-1573(199909)13:6<529::aid-ptr481>3.0.co;2-x Preclinical
https://doi.org/10.1002/(sici)1099-1573(199909)13:6<529::aid-ptr481>3.0.co;2-x - Zeng, P., Chen, Y., Zhang, L. and Xing, M (2019) 'Ganoderma lucidum polysaccharide used for treating physical frailty in China', Progress in Molecular Biology and Translational Science, 163, pp. 179-219. doi:10.1016/bs.pmbts.2019.02.009 Meta-analysis / review
https://doi.org/10.1016/bs.pmbts.2019.02.009 - Wu, P., Zhang, C., Yin, Y., Zhang, X., Li, Q., Yuan, L., Sun, Y., Zhou, S., Ying, S. and Wu, J (2024) 'Bioactivities and industrial standardization status of Ganoderma lucidum: A comprehensive review', Heliyon, 10(19), pp. e36987. doi:10.1016/j.heliyon.2024.e36987 Meta-analysis / review
https://doi.org/10.1016/j.heliyon.2024.e36987 - Xu, Z., Chen, X., Zhong, Z., Chen, L. and Wang, Y (2011) 'Ganoderma lucidum polysaccharides: immunomodulation and potential anti-tumor activities', The American Journal of Chinese Medicine, 39(1), pp. 15-27. doi:10.1142/S0192415X11008610 Meta-analysis / review
https://doi.org/10.1142/S0192415X11008610 - Geng, X., Zhong, D., Su, L., Lin, Z. and Yang, B (2019) 'Preventive and therapeutic effect of Ganoderma lucidum on kidney injuries and diseases', Advances in Pharmacology, 87, pp. 257-276. doi:10.1016/bs.apha.2019.10.003 Meta-analysis / review
https://doi.org/10.1016/bs.apha.2019.10.003 - Sliva, D (2004) 'Cellular and physiological effects of Ganoderma lucidum (Reishi)', Mini Reviews in Medicinal Chemistry, 4(8), pp. 873-879. doi:10.2174/1389557043403323 Meta-analysis / review
https://doi.org/10.2174/1389557043403323 - Boh, B., Berovic, M., Zhang, J. and Zhi-Bin, L (2007) 'Ganoderma lucidum and its pharmaceutically active compounds', Biotechnology Annual Review, 13, pp. 265-301. doi:10.1016/S1387-2656(07)13010-6 Meta-analysis / review
https://doi.org/10.1016/S1387-2656(07)13010-6 - Bao, X. et al (2001) 'Structural requirements for the immunological activities of polysaccharides from Ganoderma lucidum', 41(9), pp. 2603--2611. Traditional / reference
https://scholar.google.com/scholar?q=Structural%20requirements%20for%20the%20immunological%20activities%20of%20polysaccharides%20from%20Ganoderma%20lucidum - Jin, X. et al (2012) 'Ganoderma lucidum (Reishi mushroom) for cancer treatment'. Traditional / reference
https://scholar.google.com/scholar?q=Ganoderma%20lucidum%20%28Reishi%20mushroom%29%20for%20cancer%20treatment - Wachtel-Galor, S., Yuen, J., Buswell, J.A. and Benzie, I.F.F (2011) 'Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom'. Traditional / reference
https://scholar.google.com/scholar?q=Ganoderma%20lucidum%20%28Lingzhi%20or%20Reishi%29%3A%20A%20Medicinal%20Mushroom - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003 - Ahn, J.Y. and Seok, S.J. and Song, J.E. and Choi, J.H. and Han, S.H. and Choi, J.Y. and Kim, C.O. and Song, Y.G. and Kim, J.M (2013) 'Two cases of mushroom poisoning by Podostroma cornu-damae', Yonsei Medical Journal, 54(1), pp. 265-8. doi:10.3349/ymj.2013.54.1.265 Clinical study
https://doi.org/10.3349/ymj.2013.54.1.265 - Choe, S. and In, S. and Jeon, Y. and Choi, H. and Kim, S (2018) 'Identification of trichothecene-type mycotoxins in toxic mushroom Podostroma cornu-damae and biological specimens from a fatal case by LC-QTOF/MS', Forensic Science International, 291, pp. 234-244. doi:10.1016/j.forsciint.2018.08.043 Clinical study
https://doi.org/10.1016/j.forsciint.2018.08.043
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.